European Union

Drug Users in Prison

(Drug Users in Prison) "Cannabis is the illicit drug with the highest reported level of lifetime prevalence among prisoners, with between 12% and 70% having tried it at some time in their lives. This reflects drug use experience in the general population, although the levels there are lower (1.6% to 33% among 15- to 64-year-olds). Levels of use of cocaine, Europe’s second most commonly reported illicit drug, both inside and outside prison, are also much higher among prisoners (lifetime prevalence of 6–53%) than among the general population (0.3–10%).

Cannabis Offenses in the EU, 1999-2004

(Cannabis Offenses in the EU, 1999-2004) "In 1999–2004, the number of 'reports' of drug law offences involving cannabis increased overall in the majority of reporting countries, while decreases were evident in Italy and Slovenia. Over the same period, the proportion of drug offences involving cannabis increased in Germany, Spain, France, Lithuania, Luxembourg, Portugal, the United Kingdom and Bulgaria, while it remained stable overall in Ireland and the Netherlands, and decreased in Belgium, Italy, Austria, Slovenia and Sweden.

Need for Social Reintegration and Services for Drug Users

(Need for Social Reintegration and Services for Drug Users) "Drug use is an important factor that increases the likelihood of concurrent social exclusion (EMCDDA, 2003a). However, there is no clear causality between drug use and social exclusion, as either may lead to the other, and both may be preceded and caused by (unknown) third factors. Many problem drug users already experienced problems in other spheres of life, including social exclusion, prior to their drug use.

Availability of Specialized Treatment Services

(Availability of Specialized Treatment Services) "Treatment units or programmes that exclusively service one specified target group are a common phenomenon across the EU. Children and young people under the age of 18 are treated in specialised agencies in 23 countries; the treatment of drug users with psychiatric co-morbidity takes place in specialised agencies in 18 countries; and women-specific services are reported to exist in all countries except Cyprus, Latvia, Lithuania, Bulgaria and Turkey.